GETI_B: Strong Q2 2026 growth and profitability, led by Acute Care Therapies and Life Science
Organic sales and order intake grew strongly in Q2 2026, with profitability and cash flow significantly improved by operational gains and a major tariff refund. Acute Care Therapies and Life Science segments led growth, while APAC lagged. Outlook for 2026 remains positive despite ongoing geopolitic…